Veeva Systems Inc. (VEEV)

Veeva Systems Inc. (NYSE: VEEV) is the global leader in cloud-based software for the life sciences industry, providing a unified platform for clinical, regulatory, and commercial operations. Led by Founder and CEO Peter Gassner, the company’s mission is to build the industry-standard cloud that helps life sciences companies bring products to market faster and more efficiently. Veeva envisions a future where the "Veeva Vault" platform is the foundation for every stage of a drug’s lifecycle. As a Public Benefit Corporation (PBC), VEEV stock is a unique software play that balances shareholder returns with the advancement of the healthcare industry.

The business operations of Veeva Systems in late 2025 are defined by the rapid migration of its customers to "Veeva Vault CRM," the company’s proprietary next-generation commercial platform. In December 2025, VEEV stock investors cheered the company’s successful expansion into the "MedTech" and "Clinical Data" segments, which have significantly higher growth rates than its mature CRM business. The company’s core products include Vault Clinical, Vault Quality, and its industry-leading CRM software used by the majority of global pharmaceutical giants. The future business strategy for VEEV stock involves leveraging AI through its "Veeva Compass" data platform to provide real-time patient and prescriber insights. Throughout 2025, the company maintained an exceptional operating margin of nearly 40%, reflecting its high-margin SaaS model and high customer retention. As the pharma industry digitalizes, the specialized software ecosystem provided by VEEV stock has become an unbreakable competitive moat, supporting the long-term growth case for the stock.

Veeva Systems stock is listed on the New York Stock Exchange under the ticker symbol VEEV. In late 2025, the VEEV stock price has shown strong recovery momentum, recently trading near $245 as the market rewards its successful CRM transition. Analysts monitoring the VEEV stock price emphasize the company’s "Mission-Critical" status within the highly regulated pharma sector. For those tracking the VEEV stock price today, the key catalysts include new Vault Clinical contract wins and the expansion of its data business. As a titan of the vertical-SaaS sector, VEEV stock remains a top selection for technology investors. The rising VEEV stock price reflects its role as the digital backbone of global life sciences.